샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793772

세계의 난치성 여포성 림프종 진단 시장

Refractory Follicular Lymphoma Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 369 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

난치성 여포성 림프종 진단 세계 시장은 2030년까지 4억 5,120만 달러에 달할 전망

2024년에 3억 5,260만 달러로 추정되는 난치성 여포성 림프종 진단 세계 시장은 2024년부터 2030년까지 CAGR 4.2%로 성장하여 2030년에는 4억 5,120만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 기구는 CAGR 4.8%를 기록하며 분석 기간 종료시에는 3억 2,840만 달러에 달할 것으로 예측됩니다. 키트 및 소모품 부문의 성장률은 분석 기간 동안 CAGR 2.6%로 추정됩니다.

미국 시장은 추정 9,610만 달러, 중국은 CAGR 7.8%로 성장 예측

미국의 난치성 여포성 림프종 진단 시장은 2024년에 9,610만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간 2024년부터 2030년까지 CAGR 7.8%로 성장하여 2030년에는 예측 시장 규모 9,300만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.7%와 3.3%로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예측됩니다.

세계의 난치성 여포성 림프종 진단 시장 - 주요 동향과 촉진요인 정리

난치성 여포성 림프종의 진단 전략이 복잡해지는 이유는 무엇일까?

비호지킨림프종(NHL)의 아형인 난치성 여포성 림프종(RFL)은 일선 치료 요법에 대한 내성과 재발 경향으로 인해 진단에 큰 어려움을 겪고 있습니다. 치료가 더욱 표적화되고 환자별로 세분화됨에 따라, 이러한 치료 결정을 뒷받침하는 진단학은 빠르게 발전해야 합니다. 현재 RFL의 진단 전략은 병리조직학적 확인, 면역표현형 분류, 유전학적 및 분자생물학적 프로파일링, 첨단 영상 진단 기술을 결합한 다인자 평가에 의존하고 있습니다. 난치성 질환과 반응성 아형을 조기에 정확하게 구분해야 하는 필요성으로 인해 정밀 진단 도구에 대한 관심이 높아지고 있습니다.

기존의 생검과 면역조직화학은 여전히 RFL을 확인하는 데 기초가 되고 있지만, 치료 저항성을 암시하는 분자 시그니처를 검출하는 데는 한계가 있습니다. 그 결과, 치료 저항성 및 무진행 생존에 관여하는 EZH2, BCL2, CREBBP의 고위험 돌연변이를 확인하기 위해 유전자 발현 프로파일링 및 차세대 염기서열 분석(NGS)의 채택이 증가하고 있습니다. 이러한 분자진단법은 임상의에게 임상 병기 분류의 틀을 넘어 환자 분류의 새로운 길을 제공하고, 생물학적 정보에 기반한 계층화 및 실시간 치료 모니터링으로의 전환을 촉진하고 있습니다.

어떤 진단 양식이 임상적 의사결정을 형성하고 있는가?

유세포 분석 및 형광 in situ hybridization(FISH)은 여포성 림프종에서 t(14;&18)과 같은 특징적인 전좌를 검출하는 데 도움이 되며, 오랫동안 림프종 진단의 주축으로 사용되어 왔습니다. 그러나 난치성 질환의 경우, 이러한 도구는 현재 더 광범위한 돌연변이 상황을 제공하는 NGS 패널과 함께 사용되는 경우가 많습니다. 액체 생검, 특히 순환 종양 DNA(ctDNA) 프로파일링은 비침습적이고 질병 부하, 클론 진화, 미세잔존병변(MRD)을 추적하는 데 유용하기 때문에 RFL 진단에 침투하고 있습니다.

또한, PET(양전자방사선단층촬영)과 CT(컴퓨터단층촬영)를 결합한 검사(PET-CT)는 치료 반응성 평가와 난치성 진행을 감지하는 데 있어 핵심적인 역할을 하고 있습니다. 대사성 종양 부피와 병변 전체의 해당을 정량화하는 새로운 영상 바이오마커는 RFL 재발을 예측하는 데 있어 그 예측 가치를 연구하고 있습니다. 세포유전학적 측면에서는 비교 유전체 하이브리드화(CGH) 어레이와 디지털 핵형 분석이 난치성 관련 염색체 이상에 대한 귀중한 정보를 제공하여 보다 맞춤화된 치료 계획에 기여하고 있습니다.

정밀의료와 동반진단은 시장 상황에 어떤 영향을 미치고 있는가?

RFL 치료에서 EZH2 억제제, PI3K 억제제, 이중특이성항체 등 표적 치료제의 등장은 진단약 시장의 성장과 혁신 궤도에 큰 영향을 미치고 있습니다. 신규 치료제의 유효성 판단을 위해서는 동반진단약(CDx)이 필요한 경우가 많아 제약사와 진단약 기업은 그 어느 때보다 긴밀한 협력 관계를 구축하고 있습니다. 이러한 변화로 인해 멀티플렉스 분석 및 맞춤형 NGS 패널을 통해 예측 바이오마커를 검증하는 CDx 키트에 대한 수요가 급증하고 있습니다.

또한, RFL 치료에서 CAR-T 세포 치료 및 기타 면역 종양학 플랫폼의 채택이 증가함에 따라 종양 돌연변이 부하(TMB), PD-L1 발현, 배아 중심 B 세포 프로파일링을 포함한 종합적인 치료 전 진단 평가가 필요합니다. 진단 워크플로우에는 AI 지원 병리 및 생물정보학 플랫폼이 통합되어 있어 멀티오믹 데이터세트를 해석하고 위험도 계층화 모델을 생성할 수 있습니다. 이러한 도구는 종양 이질성, 잠재적 내성 경로, 실시간 반응 예측 등 난치성 환자 관리에 필수적인 기능에 대한 인사이트를 제공함으로써 의사결정을 강화할 수 있습니다.

난치성 여포성 림프종 진단 시장의 성장을 촉진하는 요인은?

난치성 여포성 림프종 진단 시장의 성장은 비호지킨림프종 발병률 증가, 난치성 및 재발 사례 증가, 바이오마커 유도 진단을 필요로 하는 치료 파이프라인의 확대 등 여러 가지 상호 연관된 요인에 의해 주도되고 있습니다. 여포성 림프종은 전체 비호지킨림프종의 약 20%를 차지하며, 상당수가 난치성 단계로 진행되기 때문에 조기에 정확하게 검출할 수 있는 방법에 대한 요구가 높아지고 있습니다. 특히, 첫 치료 후 24개월 이내에 재발한 환자의 예후는 좋지 않으며, 이러한 사례를 적시에 파악하는 것은 치료적 개입에 매우 중요합니다.

진단약이 맞춤형 종양학 가치사슬에 편입되는 것도 시장 성장세를 가속화하고 있습니다. FDA 및 EMA와 같은 규제 기관은 새로운 치료 및 관련 진단 약품에 대한 신속한 승인을 부여하고 있으며, 상환 프레임워크는 점점 더 바이오마커에 기반한 접근 방식을 선호하고 있습니다. 또한, 임상시험, 바이오뱅크 기반, 중개연구에 대한 투자가 증가하고, 조직 저장소 및 환자 데이터세트에 대한 접근이 확대되면서 바이오마커 탐색 및 분석법 개발의 혁신이 가속화되고 있습니다. 암 분야가 맞춤형 치료 모델로 더욱 발전함에 따라 난치성 여포성 림프종 진단 시장은 기술 주도의 강력한 성장세를 이어갈 것으로 보입니다.

부문

제품(장비, 키트, 소모품), 방법(면역조직화학법, In-situ 하이브리다이제이션법, 중합효소 연쇄 반응법, 기타 방법), 최종사용자(병원 최종사용자, 진단 센터 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Abcam Limited
  • AbbVie Inc.
  • ADC Therapeutics S.A.
  • Agilent Technologies, Inc.
  • Allogene Therapeutics
  • AstraZeneca
  • Bayer AG
  • Beckman Coulter, Inc.
  • BeiGene
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Genmab
  • IGM Biosciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Xynomic Pharmaceuticals, Inc.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.26

Global Refractory Follicular Lymphoma Diagnostics Market to Reach US$451.2 Million by 2030

The global market for Refractory Follicular Lymphoma Diagnostics estimated at US$352.6 Million in the year 2024, is expected to reach US$451.2 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$328.4 Million by the end of the analysis period. Growth in the Kits & Consumables segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$96.1 Million While China is Forecast to Grow at 7.8% CAGR

The Refractory Follicular Lymphoma Diagnostics market in the U.S. is estimated at US$96.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.0 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Refractory Follicular Lymphoma Diagnostics Market - Key Trends & Drivers Summarized

Why Are Diagnostic Strategies for Refractory Follicular Lymphoma Becoming More Complex?

Refractory follicular lymphoma (RFL), a subtype of non-Hodgkin lymphoma (NHL), poses significant diagnostic challenges due to its resistance to frontline treatment regimens and its tendency to relapse. As therapies become more targeted and patient-specific, the diagnostics supporting these treatment decisions have had to evolve rapidly. Diagnostic strategies for RFL now depend on a multifactorial assessment, combining histopathological confirmation, immunophenotyping, genetic and molecular profiling, and advanced imaging techniques. The need to accurately distinguish refractory disease from responsive subtypes at early stages is driving substantial interest in precision diagnostic tools.

Traditional biopsy and immunohistochemistry remain foundational in confirming RFL, but limitations arise when trying to detect molecular signatures that suggest treatment resistance. As a result, gene expression profiling and next-generation sequencing (NGS) are increasingly employed to identify high-risk mutations in EZH2, BCL2, and CREBBP, which are implicated in treatment resistance and poor progression-free survival. These molecular diagnostics are offering clinicians new pathways to classify patients beyond clinical staging, fostering the move toward biologically informed stratification and real-time therapeutic monitoring.

Which Diagnostic Modalities Are Shaping Clinical Decision-Making?

Flow cytometry and fluorescence in situ hybridization (FISH) have long served as mainstays in lymphoma diagnostics, helping detect hallmark translocations like t(14;18) in follicular lymphoma. However, in the case of refractory disease, these tools are now often used in conjunction with NGS panels, which provide a broader mutational landscape. Liquid biopsies-particularly circulating tumor DNA (ctDNA) profiling-are gaining ground in RFL diagnostics due to their non-invasive nature and utility in tracking disease burden, clonal evolution, and minimal residual disease (MRD).

Additionally, positron emission tomography (PET) combined with computed tomography (PET-CT) continues to play a central role in assessing treatment response and detecting refractory progression. Emerging imaging biomarkers that quantify metabolic tumor volume and total lesion glycolysis are being investigated for their predictive value in RFL recurrence. On the cytogenetic front, comparative genomic hybridization (CGH) arrays and digital karyotyping are providing valuable information on chromosomal abnormalities associated with refractory behavior, contributing to more tailored therapeutic planning.

How Are Precision Medicine and Companion Diagnostics Influencing the Market Landscape?

The rise of targeted therapies such as EZH2 inhibitors, PI3K inhibitors, and bispecific antibodies in RFL treatment is heavily influencing the growth and innovation trajectory of the diagnostics market. With new therapeutic agents often requiring companion diagnostics (CDx) for efficacy determination, pharmaceutical and diagnostic firms are collaborating more closely than ever. This shift has created a surge in demand for CDx kits that validate predictive biomarkers through multiplex assays and custom NGS panels.

Moreover, the increasing adoption of CAR-T cell therapy and other immuno-oncology platforms in RFL treatment requires comprehensive pre-treatment diagnostic assessments, including tumor mutational burden (TMB), PD-L1 expression, and germinal center B-cell profiling. Diagnostic workflows are also integrating AI-assisted pathology and bioinformatics platforms capable of interpreting multi-omic datasets and generating risk stratification models. Such tools enhance decision-making by offering insights into tumor heterogeneity, potential resistance pathways, and real-time response prediction-features critical in managing refractory cases.

What Factors Are Driving the Growth of the Refractory Follicular Lymphoma Diagnostics Market?

The growth in the refractory follicular lymphoma diagnostics market is driven by multiple interrelated factors, including the increasing incidence of non-Hodgkin lymphoma, the rising rate of refractory and relapsed cases, and expanding treatment pipelines that require biomarker-guided diagnostics. With follicular lymphoma comprising approximately 20% of all NHL cases, and a significant fraction progressing to refractory stages, the demand for early and accurate detection modalities is intensifying. In particular, patients who relapse within 24 months of initial therapy exhibit poorer prognosis, making timely identification of such cases crucial for therapeutic intervention.

The integration of diagnostics into the value chain of personalized oncology is also accelerating market momentum. Regulatory bodies such as the FDA and EMA are granting fast-track approvals to diagnostics linked with novel therapies, while reimbursement frameworks are increasingly favoring biomarker-based approaches. Furthermore, rising investments in clinical trials, biobank infrastructure, and translational research are expanding access to tissue repositories and patient datasets, fueling innovation in biomarker discovery and assay development. As the oncology field moves further toward tailored care models, the market for refractory follicular lymphoma diagnostics will continue to experience robust and technology-driven growth.

SCOPE OF STUDY:

The report analyzes the Refractory Follicular Lymphoma Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Instruments, Kits & Consumables); Method (Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method, Other Methods); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abcam Limited
  • AbbVie Inc.
  • ADC Therapeutics S.A.
  • Agilent Technologies, Inc.
  • Allogene Therapeutics
  • AstraZeneca
  • Bayer AG
  • Beckman Coulter, Inc.
  • BeiGene
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Genmab
  • IGM Biosciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Xynomic Pharmaceuticals, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Refractory Follicular Lymphoma Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expansion of Genomic Testing Capabilities Throws the Spotlight on Precision Oncology Diagnostics
    • Rise in Cancer Incidence Rates Spurs Demand for Early and Accurate Lymphoma Detection
    • Integration of AI in Histopathological Image Analysis Enhances Diagnostic Speed and Accuracy
    • Biomarker Discovery Initiatives Strengthen the Case for Molecular-Based Diagnostic Protocols
    • Adoption of Liquid Biopsy Techniques Propels Minimally Invasive Screening Modalities
    • Global Increase in Biobank Networks Drives Availability of High-Quality Sample Repositories
    • Inclusion of FL-Specific Markers in Clinical Panels Accelerates Test Adoption Rates
    • Collaborations Between Diagnostic Labs and Pharma Firms Support Companion Diagnostics
    • Shift Toward Personalized Cancer Management Expands Adoption of Advanced Assays
    • Improved Reimbursement Policies in Developed Markets Boost Market Accessibility
    • Digital Pathology Platforms Enable Remote Expert Review and Diagnostic Standardization
    • Proliferation of Point-of-Care Molecular Diagnostic Devices Enhances Clinical Decision Making
    • Emergence of Multi-Omics Testing Approaches Deepens Disease Characterization
    • Expanding Application of NGS in Hematologic Cancers Strengthens Testing Utility
    • Regulatory Approvals for Novel Diagnostic Kits Support Market Scalability
    • R&D Investments in Non-Invasive Genotyping Techniques Accelerate Product Innovation
    • Awareness Programs on Early Lymphoma Detection Encourage Screening Uptake
    • Integration of Diagnostic Data With EHR Systems Enhances Oncologist Workflow Efficiency
    • Quality Accreditation Requirements Drive Upgradation of Lab Infrastructure
    • Strategic Hospital-Laboratory Tie-Ups Improve Outreach and Commercial Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Refractory Follicular Lymphoma Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Refractory Follicular Lymphoma Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunohistochemistry Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunohistochemistry Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunohistochemistry Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for In Situ Hybridization Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for In Situ Hybridization Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for In Situ Hybridization Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Polymerase Chain Reaction Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Polymerase Chain Reaction Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Refractory Follicular Lymphoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Refractory Follicular Lymphoma Diagnostics by Product - Instruments and Kits & Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Product - Percentage Breakdown of Value Sales for Instruments and Kits & Consumables for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Refractory Follicular Lymphoma Diagnostics by Method - Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by Method - Percentage Breakdown of Value Sales for Immunohistochemistry Method, In Situ Hybridization Method, Polymerase Chain Reaction Method and Other Methods for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Refractory Follicular Lymphoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Refractory Follicular Lymphoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제